Curasight A/S reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was DKK 26.17 million compared to DKK 18.35 million a year ago. Basic loss per share from continuing operations was DKK 1.32 compared to DKK 0.92 a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.5 DKK | +5.00% | +5.63% | -40.85% |
16/04 | Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients | CI |
12/04 | Curasight A/S Announces Board Changes | CI |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-40.85% | 30.18M | |
+23.37% | 47.02B | |
+48.83% | 41.86B | |
-0.94% | 41.76B | |
-5.86% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- CURAS Stock
- News Curasight A/S
- Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2023